Patrick Daniele, MS

Evidera

Disclosure(s): GSK: Advisor/Consultant; ViiV Healthcare: Advisor/Consultant

Poster(s):

• (P-528) Opportunities for PrEP Awareness and Engagement: A Survey among Healthcare-Seeking Cisgender Women in the US
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-545) Feasibility, Fidelity, and Effectiveness of Administering CABENUVA in Infusion Centers
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-1424) Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT